The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of United Therapeutics in a research report ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

"The stock remains at a discounted level versus historical ranges," Cherny said. "The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its ...

Leerink Partnrs issued their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...